Learn about biomarker testing to see if you could be eligible for TECELRA
View HCP Site View Patient Site
Full Prescribing Information Medication Guide
Find an ATC Connect with us

How was TECELRA studied and what were the results?

TECELRA is the only T-cell therapy shown to shrink synovial sarcoma tumors by the first scan

Synovial sarcoma tumors shrank or disappeared in 44% of patients treated with TECELRA. Among those who responded to TECELRA, half experienced a response within 4.6 weeks

In a clinical study, 137 patients with advanced synovial sarcoma were given TECELRA to evaluate the efficacy and safety of the treatment. This study was open-label, meaning all patients knew they received TECELRA. To be in this study, patients had to have the 2 required biomarkers (HLA-A*02 and MAGE-A4) and have previously received at least one systemic therapy, including chemotherapy, for their advanced synovial sarcoma (median: 2). The median age for those in the study was 38 years (range: 13-73 years); 53% were men and 47% were women.

TECELRA was able to shrink or eliminate synovial sarcoma tumors in the study

44%

of patients saw their tumor shrink or disappear†

Icon of a synovial sarcoma tumor and decreasing arrow

40%

of patients saw their tumor shrink

Icon of a synovial sarcoma tumor and an X

4%

of patients saw their tumor disappear

AMONG PATIENTS WHO SAW THEIR TUMOR SHRINK or disappear†:

HALF saw results with TECELRA by

4.6 weeks

48%

maintained their response for 6 months or longer

32%

maintained their response for 2 years or longer

Not an actual patient.

HLA=human leukocyte antigen; MAGE=melanoma-associated antigen.

Median is the middle number in a group of numbers arranged from lowest to highest.
†

43.8% of a total 137 patients in the study saw results with TECELRA.

Keep exploring

Take the first step and ask your doctor about biomarker testing today. The discussion guide below can help you be prepared.

INDICATION and IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION
and INDICATION

What is TECELRA?

TECELRA® is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you.

IMPORTANT SAFETY INFORMATION

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.

INDICATION and IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY
INFORMATION and INDICATION

What is TECELRA?

TECELRA® is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you.

IMPORTANT SAFETY INFORMATION

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.

After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 2 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 2 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.

Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.

The most common side effects of TECELRA include nausea, fatigue, musculoskeletal pain, infection, fever (100.4°F/38°C or higher), constipation, vomiting, headache, diarrhea, cough, fast heart rate, swelling, shortness of breath, rash, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, decreased red blood cell count, and decreased platelet count.

You are encouraged to report side effects to the FDA at (800) FDA‑1088 or www.fda.gov/medwatch or to US WorldMeds at 1-855-246-9232.

What is TECELRA?

TECELRA® is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you.

Please see Medication Guide, including Important Warning.

You are now leaving
this site

This link will take you to a third-party site that is not owned by US WorldMeds. Click “OK” if you would like to proceed or click “Cancel” to stay on this site.

OK
Cancel